Company Profile
ABION is a pharmaceutical biotech Company in South Korea and globally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer
In Phase I clinical trial for breast cancer. Its portfolio also includes ABN501, a human monoclonal antibody that targets claudin 3 for treating solid cancers, ABN201, an antibody cytokine fusion protein to treat solid cancers, and ABN101, a dry powder inhaler as a prophylactic treatment for various respiratory viruses.
It is also developing ABN701 for SEBI infectious diseases; and ABN 901, ABN 902, and ABN 903 for infectious diseases related to biological disasters. Founded in 2007, Abion is based in Seoul, South Korea.